相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon et al.
LEUKEMIA (2020)
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Hartmut Goldschmidt et al.
LEUKEMIA (2020)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
Nisha S. Joseph et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo et al.
LANCET HAEMATOLOGY (2020)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Laura Rosinol et al.
BLOOD (2019)
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Edward A. Stadtmauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
Mark T. Drayson et al.
LANCET ONCOLOGY (2019)
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial
H. Goldschmidt et al.
LEUKEMIA (2018)
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
Charles Dumontet et al.
LEUKEMIA (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
Monika Engelhardt et al.
HAEMATOLOGICA (2017)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L. McCarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
Monika Engelhardt et al.
HAEMATOLOGICA (2017)
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial
Christian Straka et al.
HAEMATOLOGICA (2016)
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
Monika Engelhardt et al.
HAEMATOLOGICA (2016)
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial
Christian Straka et al.
HAEMATOLOGICA (2016)
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
Monika Engelhardt et al.
HAEMATOLOGICA (2016)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo et al.
BLOOD (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay et al.
LANCET ONCOLOGY (2015)
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
E. K. Mai et al.
LEUKEMIA (2015)
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
H. W. Auner et al.
BONE MARROW TRANSPLANTATION (2015)
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Cecilie Blimark et al.
HAEMATOLOGICA (2015)
Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents
M. Merz et al.
ANNALS OF ONCOLOGY (2014)
Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation
Manish Sharma et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
How we manage autologous stem cell transplantation for patients with multiple myeloma
Morie A. Gertz et al.
BLOOD (2014)
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Monika Engelhardt et al.
HAEMATOLOGICA (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Lotfi Benboubker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
A. Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
Francesca Gay et al.
BLOOD (2013)
Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
Antonio Palumbo et al.
BLOOD (2010)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
Michele Cavo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party
BM Augustson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Forest plots and the interpretation of subgroups
J Cuzick
LANCET (2005)
Single versus double autologous stem-cell transplantation for multiple myeloma
M Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
P Moreau et al.
BLOOD (2002)